
It’s estimated that over half of the world’s population is at risk for malaria. For many families, protecting themselves from this disease is a daily concern, with children under five being the most vulnerable group.
More than 20 years ago, SC Johnson started looking at how we could help raise standards of living and provide opportunities for a better quality of life for the 4 billion people at the base of the world’s economic pyramid.
The SC Johnson team dedicated to this initiative is working to reduce mosquito populations and encourage education about mosquito-borne diseases like malaria, and create sustainable business solutions to help strengthen communities in developing countries.
More than 20 years ago, SC Johnson started looking at how we could help raise standards of living and provide opportunities for a better quality of life for the 4 billion people at the base of the world’s economic pyramid.
The SC Johnson team dedicated to this initiative is working to reduce mosquito populations and encourage education about mosquito-borne diseases like malaria, and create sustainable business solutions to help strengthen communities in developing countries.
All of the work SC Johnson has done would not be possible without partners and leaders from around the world. Throughout the world, we have initiatives that leverage the company’s expertise and capabilities to benefit the world’s most vulnerable populations.
SC Johnson and The United Republic of Tanzania Launch Latest Initiative in Partnership to Eradicate Malaria
SC Johnson and the government of Tanzania announced a new public-private partnership in the fight against malaria. The leading global manufacturer of household pest control products will expand on previous disease-prevention investments in Tanzania by directing USD 1.5 million to support the development of malaria prevention education programming, distribution of spatial repellents through public health channels, and construction of new community health clinics to support families in rural, hard-to-reach areas.
All of the work SC Johnson has done would not be possible without partners and leaders from around the world. Throughout the world, we have initiatives that leverage the company’s expertise and capabilities to benefit the world’s most vulnerable populations.
SC Johnson and The United Republic of Tanzania Launch Latest Initiative in Partnership to Eradicate Malaria
SC Johnson and the government of Tanzania announced a new public-private partnership in the fight against malaria. The leading global manufacturer of household pest control products will expand on previous disease-prevention investments in Tanzania by directing USD 1.5 million to support the development of malaria prevention education programming, distribution of spatial repellents through public health channels, and construction of new community health clinics to support families in rural, hard-to-reach areas.
SC Johnson has developed spatial repellent products aimed to address challenges of coverage, cost, and access. The products, Mosquito Shield™ and Guardian™, can be distributed to hard-to-access areas at low cost, providing additional protection to families who need it most.
SC Johnson and Tanzania are giving the company’s two innovative spatial repellents, Mosquito Shield™ and Guardian™, to at-risk populations through global public health partners at no cost. The initiative comes as the company is in the process of obtaining World Health Organization policy recommendations for the two tools – a catalysing action point that would accelerate critical partnerships and funding in support of large-scale distribution efforts.
Repels Mosquito Vectors of Disease
Efficacy tests indicate spatial repellents significantly reduce bites from mosquitoes that may carry disease, including ones that transmit:
About Mosquito Shield™ and Guardian™
The Mosquito Shield™ spatial repellent, developed by a dedicated team in 2017, is an easy-to-use product that can help protect a semi-enclosed or enclosed space from mosquitoes without requiring electricity or a flame to work. It has been through trials in Indonesia and Peru, with promising results, and is now in large-scale clinical trials funded by UNITAID in Kenya, Mali and Sri Lanka.
Formed in 2002, The Global Fund has disbursed more than US$55.4 billion in the fight against HIV, TB and malaria and has supported programs that have saved 50 million lives to date.
The Global Fund is also the leading funding agency in global health, providing 63% of all international financing for malaria programs, and has invested more than $16.4 billion in malaria control programs as of June 2022.
SC Johnson is one of the newest members to join the Fund’s Private Sector Constituency (PSC), and plays a guiding role in providing technical know-how, shaping policies and priorities, and representing the private sector in Fund board meetings.
The MENTOR Initiative acts in some of the world’s most austere and vulnerable communities, who are often devastated and forgotten. Regardless of race, creed or nationality, MENTOR strives to deliver disease control to populations at greatest risk of suffering and death. The MENTOR Initiative saves lives in emergencies through tropical disease control and then stays to help people recover from crises with dignity, working side-by-side with communities, health workers and health authorities to leave a lasting impact.
In partnership with the MENTOR initiative, SC Johnson has donated and distributed Mosquito Shield™ to combat the rise of CL in conflict settings in Syria. These single sheets are hung up in the home to provide a portable, simple and stable tool for protection against flying insects. To date, we’ve collectively protected 76,000 people in Syria and Yemen with Mosquito Shield™ through this effort.
The University of Notre Dame is one of America’s leading undergraduate teaching institutions and has been at the forefront of research and scholarship in the health sector and beyond. In 2014, SCJ partnered with the University of Notre Dame and the Eijkman Institute for Molecular Biology, with funding from the Bill & Melinda Gates Foundation, to test their Mosquito Shield™ in a trial in Indonesia. In 2014, the University of Notre Dame team, in cooperation with the University of California Davis and U.S. Naval Medical Research Unit Six, led another clinical trial of Mosquito Shield™ based in Peru and the study found that the production appeared to reduce Aedes-borne virus infections rates by an estimated 34%
Now, using what we’ve learned, an optimized version of the Mosquito Shield™ will be used in large-scale clinical trials funded by UNITAID in Kenya, Mali, and Sri Lanka.